Ethiopia to India Pharmaceutical Import

The pharmaceutical trade corridor between Ethiopia and India has experienced modest activity from 2022 to 2026. Between 2022 and 2026, Ethiopia exported a total of $25 USD worth of finished pharmaceutical formulations to India, comprising two shipments. The sole supplier from Ethiopia during this period was the ARMAUER HANSEN RESEARCH INSTITUTE, which provided plasma products. The recipient in India was CLIANTHA RESEARCH LIMITED, which received both shipments. This limited trade volume indicates a nascent and underdeveloped trade relationship in the pharmaceutical sector between the two nations.

Ethiopia's contribution to India's pharmaceutical imports is negligible, accounting for only $25 USD over the 2022-2026 period. This minimal share underscores Ethiopia's limited presence in India's pharmaceutical import landscape. The sole product imported from Ethiopia was plasma, highlighting the narrow scope of pharmaceutical categories involved in this trade.

Between 2024 and 2026, there were no significant policy changes, trade agreements, or regulatory harmonization efforts between Ethiopia and India in the pharmaceutical sector. The trade volume remained static, indicating a lack of substantial developments in this bilateral corridor during the specified period.

For Ethiopian companies aiming to export pharmaceutical products to India, obtaining registration with the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:

1. Application Submission: Companies must register on the CDSCO SUGAM portal, providing details about the applicant and the products intended for import.

2. Document Submission: Essential documents include the Certificate of Pharmaceutical Product (COPP), Good Manufacturing Practice (GMP) certificate, free sale certificate, and a power of attorney.

3. Review and Approval: CDSCO reviews the application and may conduct inspections to ensure compliance with Indian standards.

4. License Issuance: Upon successful evaluation, CDSCO issues the necessary import license, authorizing the company to export pharmaceutical products to India.

The entire process can take several months, depending on the completeness of the application and the efficiency of the review process.

India requires that manufacturing sites in Ethiopia adhere to Good Manufacturing Practice (GMP) standards as per WHO guidelines. Ethiopian manufacturers must obtain WHO prequalification, which involves demonstrating compliance with international quality standards. CDSCO may conduct inspections to verify adherence to these standards before granting approval for importation into India.

To import pharmaceutical products into India, Ethiopian companies must provide:

• Import License (Form 10): Issued by CDSCO, authorizing the import of specific pharmaceutical products.

• Registration Certificate: Confirms that the product is registered and approved for sale in the country of origin.

• No Objection Certificate (NOC): Indicates that the exporting country's regulatory authority has no objection to the export of the product.

• Test License: Allows for the importation of products for testing or analysis purposes.

Additionally, compliance with Indian customs procedures, including proper labeling and packaging, is essential for smooth importation.

The pharmaceutical imports from Ethiopia to India are limited to plasma products, with a total value of $25 USD over the 2022-2026 period. This singular product category indicates a lack of diversity in the types of pharmaceutical products imported from Ethiopia to India.

Given the minimal trade volume and limited product range, there is currently no significant importation of innovator drugs, novel formulations, or advanced therapies from Ethiopia to India. The trade is predominantly restricted to basic pharmaceutical products like plasma.

The negligible import volume from Ethiopia to India suggests that factors such as patent protection, technology gaps, quality requirements, and disease burden are not significant drivers for importing pharmaceutical products from Ethiopia. The limited trade may be attributed to other considerations, including cost-effectiveness and availability of alternative suppliers.

India's import tariff structure for pharmaceutical formulations includes:

• Most Favored Nation (MFN) Tariff Rates: Standard rates applied to imports from all WTO member countries.

• Basic Customs Duty: A duty imposed on imported goods, varying based on product classification.

• Integrated Goods and Services Tax (IGST): A tax levied on imported goods, applicable at the time of importation.

• Health Cess: An additional levy on imported medical devices and drugs, intended to fund health initiatives.

Specific duty rates and taxes depend on the product classification and prevailing government policies.

As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Ethiopia concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but no bilateral agreements have been established to facilitate pharmaceutical trade.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. Compulsory licensing provisions allow the government to grant licenses to third parties under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported pharmaceuticals, to ensure affordability and accessibility.

Pharmaceutical shipments from Ethiopia to India are typically transported via sea routes, with transit times varying based on the specific ports of departure and arrival. Air freight is also an option, offering faster delivery times but at higher costs. The reliability of these routes depends on factors such as weather conditions, geopolitical stability, and port efficiency.

Ethiopia's primary export ports include the Port of Djibouti, which handles a significant portion of the country's international trade. In India, major import ports include the Jawaharlal Nehru Port in Mumbai and the Chennai Port, both equipped to handle pharmaceutical shipments. The efficiency and capacity of these ports are crucial for the timely and safe delivery of pharmaceutical products.

Indian customs procedures for pharmaceutical imports involve:

• Customs Clearance: Ensuring that all import documentation is accurate and complete to facilitate smooth clearance.

• CDSCO Testing: Imported pharmaceutical products may be subject to testing by CDSCO to verify compliance with Indian standards.

• Cold Chain Compliance: Maintaining the required temperature conditions during storage and transportation to preserve product efficacy.

• Good Distribution Practice (GDP): Adhering to guidelines that ensure the quality and integrity of pharmaceutical products throughout the supply chain.

Despite being a major pharmaceutical manufacturer, India imports certain specialized products, including plasma, to meet specific medical needs. The importation of plasma from Ethiopia may be driven by factors such as cost-effectiveness, availability, and the need to diversify sources.

As of March 2026, there are no significant Ethiopian pharmaceutical companies operating in India. The limited trade volume suggests that Ethiopian companies have not established a substantial presence in the Indian market.

India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. While these efforts may lead to increased self-reliance, the demand for specialized products like plasma may continue to necessitate imports from countries like Ethiopia.

India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Ethiopia's share in this import landscape is minimal, with a total of $25 USD over the 2022-2026 period. This indicates that other countries are the primary suppliers of pharmaceutical products to India.

Ethiopian pharmaceutical products may offer competitive advantages such as cost-effectiveness and the ability to meet specific quality standards. However, the limited trade volume suggests that these advantages have not been fully realized in the Indian market.

Indian pharmaceutical manufacturers are continually developing alternatives to imported products, including